DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
MGB-BP-3 is an investigational drug.
There have been 4 clinical trials for MGB-BP-3. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2019.
The most common disease conditions in clinical trials are Vomiting, Postoperative Nausea and Vomiting, and Nausea. The leading clinical trial sponsors are MGB Biopharma Limited, Analytical Services International Limited, and Viapath.
There is one US patent protecting this investigational drug and thirteen international patents.
Recent Clinical Trials for MGB-BP-3
|Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD||Syneos Health||Phase 2|
|Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD||MGB Biopharma Limited||Phase 2|
|Effect of PNPLA3, TM6SF2 and MBOAT7 Genetic Variants on Non-alcoholic Fatty Liver Disease Therapeutic Outcome.||Federico II University||N/A|
Top disease conditions for MGB-BP-3
Top clinical trial sponsors for MGB-BP-3
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|MGB-BP-3||European Patent Office||EP2066627||2026-09-30||Start Trial|
|MGB-BP-3||United Kingdom||GB0619325||2026-09-30||Start Trial|
|MGB-BP-3||United Kingdom||GB0906908||2026-09-30||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|